Dental Research Center, Dentistry Research Institute, Department of Oral and Maxillofacial Medicine, Faculty of Dentistry, Tehran University of Medical Sciences, Tehran, Iran.
Tehran University of Medical Sciences, Tehran, Iran.
Eur Arch Paediatr Dent. 2023 Apr;24(2):249-254. doi: 10.1007/s40368-022-00776-w. Epub 2023 Feb 7.
Asthma is the most common chronic disorder in childhood. Inhaled corticosteroid therapy is currently the most effective treatment for Asthma. The oral cavity complications related to this treatment may be in terms of the changes in the innate immune system of mouth. Salivary defensin has many immunomodulatory properties. The expression of beta-defensin 2 was measured before and after inhaled corticosteroid treatment in children with asthma to determine the potential impact of corticosteroids on defensin expression.
The present study was a cohort study conducted on the patients referred to Children's Medical Center for whom a diagnosis of Asthma was confirmed, and inhaled corticosteroid therapy was prescribed. Saliva was sampled once at the stage of diagnosis and before receiving any treatment. Another salivary sample was collected 4 weeks after receiving corticosteroids. ELISA was performed to assess beta-defensin 2.
The beta-defensin 2 salivary level after inhaled corticosteroid therapy was significantly lower than before treatment. There is no significant difference in the salivary flow rate before and after treatment.
Considering the limitations of the present study, the following conclusions can be made salivary beta-defensin 2 is decreased in children with asthma after treatment with a corticosteroid inhaler. Regular dental and oral soft tissue examinations in Asthmatic children under corticosteroid therapy could be suggested.
哮喘是儿童中最常见的慢性疾病。吸入皮质类固醇治疗目前是哮喘最有效的治疗方法。这种治疗可能会引起口腔固有免疫系统的变化，从而导致口腔并发症。唾液防御素具有许多免疫调节特性。本研究旨在测量哮喘患儿在接受吸入皮质类固醇治疗前后β-防御素 2 的表达，以确定皮质类固醇对防御素表达的潜在影响。
本研究为队列研究，研究对象为儿童医疗中心确诊为哮喘并接受吸入皮质类固醇治疗的患者。在诊断阶段和接受任何治疗之前，采集一次唾液样本。在接受皮质类固醇治疗 4 周后，采集另一份唾液样本。采用 ELISA 法检测β-防御素 2。
吸入皮质类固醇治疗后唾液β-防御素 2 水平明显低于治疗前。治疗前后唾液流量无显著差异。
考虑到本研究的局限性，可以得出以下结论：哮喘儿童在接受皮质类固醇吸入器治疗后，唾液β-防御素 2 减少。建议在接受皮质类固醇治疗的哮喘儿童中定期进行牙科和口腔软组织检查。
